Raymond James Financial Services Advisors Inc. Cuts Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Raymond James Financial Services Advisors Inc. decreased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 9.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 8,975 shares of the biotechnology company’s stock after selling 974 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Sarepta Therapeutics were worth $865,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Sarepta Therapeutics by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock valued at $1,039,212,000 after purchasing an additional 41,465 shares during the period. Wellington Management Group LLP increased its position in Sarepta Therapeutics by 1.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,909,800 shares of the biotechnology company’s stock valued at $473,946,000 after purchasing an additional 54,698 shares during the period. State Street Corp increased its position in Sarepta Therapeutics by 7.9% during the 2nd quarter. State Street Corp now owns 1,913,732 shares of the biotechnology company’s stock valued at $219,161,000 after purchasing an additional 139,756 shares during the period. Geode Capital Management LLC increased its position in Sarepta Therapeutics by 3.5% during the 1st quarter. Geode Capital Management LLC now owns 1,261,971 shares of the biotechnology company’s stock valued at $173,938,000 after purchasing an additional 43,239 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Sarepta Therapeutics by 40.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,171,442 shares of the biotechnology company’s stock worth $161,461,000 after buying an additional 334,749 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $118.31 on Tuesday. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $159.89. The company has a 50 day simple moving average of $127.31 and a two-hundred day simple moving average of $110.37. The stock has a market cap of $11.11 billion, a price-to-earnings ratio of -19.33 and a beta of 0.94.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business had revenue of $396.80 million during the quarter, compared to analysts’ expectations of $387.18 million. During the same period in the previous year, the business posted ($1.24) EPS. The business’s quarterly revenue was up 53.6% compared to the same quarter last year. As a group, analysts predict that Sarepta Therapeutics, Inc. will post 2.14 earnings per share for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the sale, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Kathryn Jean Boor sold 761 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the transaction, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Stephen Mayo sold 3,135 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $122.96, for a total transaction of $385,479.60. Following the completion of the transaction, the director now owns 6,621 shares of the company’s stock, valued at $814,118.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 22,096 shares of company stock worth $2,739,419. Company insiders own 7.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on SRPT shares. UBS Group lifted their price objective on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. BMO Capital Markets started coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 price objective on the stock. TheStreet raised shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Barclays lifted their price objective on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. Finally, Needham & Company LLC cut their price objective on shares of Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $158.38.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.